Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PASART-2: preoperative pazopanib plus radiotherapy for localized soft tissue sarcoma
NL-OMON47205Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pazopanib in soft tissue sarcoma (STS) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Pathological near-complete response rate. Started Mar 2016; status: active, not recruiting.
02
Drugs
pazopanib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NL-OMON47205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47205.